Search

Displaying results 2031 - 2040 of 5419 in total
  1. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.

  2. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    by the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

  3. Drug

    Propiolactone

    go.drugbank.com/drugs/DB09348
    ApprovedWithdrawn

    [A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144]

  4. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182

  5. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste.

  6. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    The use of nadofaragene firadenovec provides a therapeutic alternative to patients seeking non-surgical alternatives for the treatment of BCG-unresponsive NMIBC. … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.

  7. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071]

  8. Drug

    Sevelamer

    go.drugbank.com/drugs/DB00658
    ApprovedInvestigational

    It is marketed by Genzyme under the trade name Renagel.

  9. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  10. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.